Research prototype, not medical advice.

09 — Stem cell exhaustion

"Integrative" hallmark in the classification of López-Otín et al., Cell 2023 (10.1016/j.cell.2022.11.001). It results largely from the accumulation of primary damage (01-05) and of the antagonistic responses (06-08).

1. Definition

With age, adult stem cells (blood, muscle, gut, skin, brain, bone) decline in number and above all in quality. They renew themselves less well, differentiate incorrectly or stay stuck in dormancy. The tissue then repairs its cell losses more slowly and less well.

In plain terms: stem cells are the body's "spare parts reserve". Over the years, the stock runs down and the parts supplied are of lower quality.

2. Mechanisms and sources

Intrinsic causes (inside the stem cell)

Extrinsic causes (the niche and the blood)

3. Symptoms and clinical manifestations

4. Interactions with the other hallmarks

5. Existing or investigational remedies

Partial reprogramming (box)

In 2006, Takahashi and Yamanaka showed that four factors (Oct4, Sox2, Klf4, c-Myc, called OSKM) take an adult cell back to the state of a pluripotent stem cell (iPS) (Takahashi 2006, 10.1016/j.cell.2006.07.024). Reprogramming cells from centenarians erases several marks of aging in vitro (Lapasset 2011, 10.1101/gad.173922.111).

The idea of partial reprogramming: apply these factors just enough to reset the epigenetic clock, without erasing the cell's identity.

In plain terms: it is like resetting a computer's settings without deleting the files. The danger is going too far and getting a cell that no longer knows what it is, or even becomes a tumour.

Table of interventions

InterventionTargetLevel of evidenceKey resultSource
Cyclic partial OSKM reprogrammingEpigenomePreclinical (progeroid mice)Improved aging traits, extended lifeOcampo 2016
OSK via viral vector (eye)Epigenome, retinal neuronsPreclinical (mice)Vision restored after injury and in old animalsLu 2020
Long-term partial reprogrammingMulti-tissue epigenomePreclinical (wild-type mice)Rejuvenated molecular markers, no tumour reportedBrowder 2022
Transient reprogramming in vitroHuman fibroblastsPreclinical (human cells)~30 years of epigenetic rejuvenationGill 2022
Senolytic ABT263 (navitoclax)Senescent cells of the bone marrowPreclinical (mice)Old HSCs rejuvenatedChang 2015
Cdc42 inhibitor (CASIN)HSC polarityPreclinical (mice)Function of old HSCs restoredFlorian 2012
Repression of p16^INK4aMuscle stem cellsPreclinical (mice)Muscle regeneration restoredSousa-Victor 2014
Caloric restriction / mTORC1 inhibitionIntestinal nichePreclinical (mice)Increased intestinal stem cell functionYilmaz 2012
Parabiosis / young blood factorsSystemic environmentPreclinical (mice)Activity of muscle and liver stem cells restoredConboy 2005
Infusion of allogeneic mesenchymal stem cellsFrailtyHuman phase I/II trialAcceptable safety, signs of functional improvement (small sample)Golpanian 2017

No intervention specifically targeting stem cell exhaustion is approved for aging. HSC transplants are approved, but for blood diseases, not for aging.

6. Open questions

7. References